Jerusalem-based Teva Pharmaceutical Industries Ltd. announced Monday that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.